BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 26617336)

  • 1. Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis.
    Bunda S; Burrell K; Heir P; Zeng L; Alamsahebpour A; Kano Y; Raught B; Zhang ZY; Zadeh G; Ohh M
    Nat Commun; 2015 Nov; 6():8859. PubMed ID: 26617336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation.
    Kano Y; Gebregiworgis T; Marshall CB; Radulovich N; Poon BPK; St-Germain J; Cook JD; Valencia-Sama I; Grant BMM; Herrera SG; Miao J; Raught B; Irwin MS; Lee JE; Yeh JJ; Zhang ZY; Tsao MS; Ikura M; Ohh M
    Nat Commun; 2019 Jan; 10(1):224. PubMed ID: 30644389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells.
    Furcht CM; Buonato JM; Skuli N; Mathew LK; Muñoz Rojas AR; Simon MC; Lazzara MJ
    J Cell Sci; 2014 Aug; 127(Pt 16):3555-67. PubMed ID: 24951116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SHP2 regulates proliferation and tumorigenicity of glioma stem cells.
    Roccograndi L; Binder ZA; Zhang L; Aceto N; Zhang Z; Bentires-Alj M; Nakano I; Dahmane N; O'Rourke DM
    J Neurooncol; 2017 Dec; 135(3):487-496. PubMed ID: 28852935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Data-Driven Computational Modeling Identifies Determinants of Glioblastoma Response to SHP2 Inhibition.
    Day EK; Zhong Q; Purow B; Lazzara MJ
    Cancer Res; 2021 Apr; 81(8):2056-2070. PubMed ID: 33574084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-Src Phosphorylates and Inhibits the Function of the CIC Tumor Suppressor Protein.
    Bunda S; Heir P; Li ASC; Mamatjan Y; Zadeh G; Aldape K
    Mol Cancer Res; 2020 May; 18(5):774-786. PubMed ID: 32029440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2.
    Chen C; Cao M; Zhu S; Wang C; Liang F; Yan L; Luo D
    Sci Rep; 2015 Dec; 5():17626. PubMed ID: 26626996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma.
    Buckarma EH; Werneburg NW; Conboy CB; Kabashima A; O'Brien DR; Wang C; Ilyas SI; Smoot RL
    Mol Cancer Res; 2020 Oct; 18(10):1574-1588. PubMed ID: 32646966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SH2 domain-containing phosphatase-2 protein-tyrosine phosphatase promotes Fc epsilon RI-induced activation of Fyn and Erk pathways leading to TNF alpha release from bone marrow-derived mast cells.
    McPherson VA; Sharma N; Everingham S; Smith J; Zhu HH; Feng GS; Craig AW
    J Immunol; 2009 Oct; 183(8):4940-7. PubMed ID: 19786542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the protein tyrosine phosphatase Shp2 in homeostasis of the intestinal epithelium.
    Yamashita H; Kotani T; Park JH; Murata Y; Okazawa H; Ohnishi H; Ku Y; Matozaki T
    PLoS One; 2014; 9(3):e92904. PubMed ID: 24675817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma.
    Sturla LM; Zinn PO; Ng K; Nitta M; Kozono D; Chen CC; Kasper EM
    Br J Cancer; 2011 Oct; 105(8):1235-43. PubMed ID: 21934682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
    Romero C; Lambert LJ; Sheffler DJ; De Backer LJS; Raveendra-Panickar D; Celeridad M; Grotegut S; Rodiles S; Holleran J; Sergienko E; Pasquale EB; Cosford NDP; Tautz L
    J Biol Chem; 2020 Feb; 295(9):2601-2613. PubMed ID: 31953320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer.
    Gu J; Han T; Ma RH; Zhu YL; Jia YN; Du JJ; Chen Y; Jiang XJ; Xie XD; Guo X
    Int J Oncol; 2014 Feb; 44(2):481-90. PubMed ID: 24297342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.
    Qiu XY; Hu DX; Chen WQ; Chen RQ; Qian SR; Li CY; Li YJ; Xiong XX; Liu D; Pan F; Yu SB; Chen XQ
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1754-1769. PubMed ID: 29510196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
    Matalkah F; Martin E; Zhao H; Agazie YM
    Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PHLDA1 promotes glioblastoma cell growth via sustaining the activation state of Ras.
    Wang J; Yao N; Hu Y; Lei M; Wang M; Yang L; Patel S; Li X; Liu K; Dong Z
    Cell Mol Life Sci; 2022 Sep; 79(10):520. PubMed ID: 36107262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-Molecule Inhibitors of Shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview.
    Mitra R; Ayyannan SR
    ChemMedChem; 2021 Mar; 16(5):777-787. PubMed ID: 33210828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The protein tyrosine phosphatase, Shp2, is required for the complete activation of the RAS/MAPK pathway by brain-derived neurotrophic factor.
    Easton JB; Royer AR; Middlemas DS
    J Neurochem; 2006 May; 97(3):834-45. PubMed ID: 16573649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noonan syndrome, the Ras-MAPK signalling pathway and short stature.
    Binder G
    Horm Res; 2009 Apr; 71 Suppl 2():64-70. PubMed ID: 19407499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.